Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7255 results

Sort By:

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Study ID: NCT05989724
Start Date: 2023-09-19
End Date: 2026-03
Study Type

Interventional

Study Phase

Phase1

No. of Participants

150

Intervention / Treatment

SON-DP

Sponsor

Qurgen Inc.

Source: clinicaltrials.gov

Share:
Add to list

Enfortumab Vedotin and Pembrolizumab in People with Bladder Cancer

Study ID: NCT05239624
Start Date: 2022-06-02
End Date: 2026-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

23

Intervention / Treatment

Emportumab Vedotin

Pembrolizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Study ID: NCT06635824
Start Date: 2024-11-25
End Date: 2029-10-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

702

Intervention / Treatment

Acasunlimab

Pembrolizumab

Docetaxel

Sponsor

Genmab

Source: clinicaltrials.gov

Share:
Add to list

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

Study ID: NCT06579196
Start Date: 2025-05-12
End Date: 2029-02
Study Type

Interventional

Study Phase

Phase2

No. of Participants

45

Intervention / Treatment

Trabedersen

Pembrolizumab

Sponsor

University of Nebraska

Source: clinicaltrials.gov

Share:
Add to list

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Study ID: NCT05106296
Start Date: 2022-02-08
End Date: 2026-09
Study Type

Interventional

Study Phase

Phase1

No. of Participants

37

Intervention / Treatment

Ibrutinib

Indoximod

Cyclophosphamide

Etoposide

Sponsor

Theodore S. Johnson

Source: clinicaltrials.gov

Share:
Add to list

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

Study ID: NCT04997096
Start Date: 2022-04-02
End Date: 2026-04-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

Exercise

Attention Control

Sponsor

Dana-Farber Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Study ID: NCT06712316
Start Date: 2025-01-07
End Date: 2030-12
Study Type

Interventional

Study Phase

Phase3

No. of Participants

982

Intervention / Treatment

Benah

Pembrolizumab

Carboplatin

Pemetrexed

Paclitaxel

Sponsor

BioNTech SE

Source: clinicaltrials.gov

Share:
Add to list

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Study ID: NCT06298916
Start Date: 2025-07
End Date: 2026-04
Study Type

Interventional

Study Phase

Phase2

No. of Participants

26

Intervention / Treatment

64Cu-LNTH-1363S

Sponsor

Lantheus Medical Imaging

Source: clinicaltrials.gov

Share:
Add to list

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Study ID: NCT05734066
Start Date: 2023-05-23
End Date: 2027-06-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

Lurbinectedin

Sponsor

Jazz Pharmaceuticals

Source: clinicaltrials.gov

Share:
Add to list

Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening

Study ID: NCT04904757
Start Date: 2019-09-19
End Date: 2023-06
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

210

Intervention / Treatment

Contrast-enhanced spectral mammography (CESM)

Sponsor

University of Virginia

Source: clinicaltrials.gov

Share:
Add to list